US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Northwest Biotherapeutics, Inc.

0.2598

+0.00883.51%

Volume:2.44M

Turnover:623.68K

Market Cap:390.10M

PE:-2.93

High:0.2647

Open:0.2572

Low:0.2500

Close:0.2510

52wk High:0.4788

52wk Low:0.1685

Shares:1.50B

Float Shares:1.38B

Volume Ratio:0.71

T/O Rate:0.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0888

EPS(LYR):-0.0575

ROE:276.45%

ROA:-141.48%

PB:-3.89

PE(LYR):-4.52

Loading ...

Overview Company News Filings

Northwest Biotherapeutics to Acquire Advent BioServices, Streamlining Operations and Enhancing Scale-Up Potential

Northwest Biotherapeutics Announces Agreement to Acquire Advent Bioservices Ltd.

THOMSON REUTERS

Northwest Biotherapeutics Announces Management Changes Following Passing of Senior VP and General Counsel Les Goldman

Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman

THOMSON REUTERS

Northwest Biotherapeutics to Present on Next Generation Dendritic Cell Treatments at Frontiers in Cancer Immunotherapy Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NWBO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NWBO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NWBO\",,,,,undefined,":{"symbol":"NWBO","market":"US","secType":"STK","nameCN":"Northwest Biotherapeutics, Inc.","latestPrice":0.2598,"timestamp":1757707200000,"preClose":0.251,"halted":0,"volume":2436454,"delay":15,"floatShares":1381857805,"shares":1501533138,"eps":-0.08878,"marketStatus":"Market Closed","change":0.0088,"latestTime":"09-12 16:00:00 EDT Delay","open":0.2572,"high":0.2647,"low":0.25,"amount":623684.9161500019,"amplitude":0.058566,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.08878,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1757923200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.251,"volumeRatio":0.7140844078255011},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NWBO\",,,,,undefined,":{"symbol":"NWBO","floatShares":1381857805,"roa":"-141.48%","roe":"276.45%","lyrEps":-0.057517,"volumeRatio":0.7140844078255011,"shares":1501533138,"dividePrice":0,"high":0.2647,"amplitude":0.058566,"preClose":0.251,"low":0.25,"week52Low":0.16845,"pbRate":"-3.89","psRate":"356.58","week52High":0.4788,"institutionHeld":0.001,"latestPrice":0.2598,"eps":-0.08878,"divideRate":0,"volume":2436454,"delay":15,"ttmEps":-0.08878,"open":0.2572,"prevYearClose":0.27475,"prevWeekClose":0.2526,"prevMonthClose":0.301,"prevQuarterClose":0.2399,"fiveDayClose":0.2526,"twentyDayClose":0.2376,"sixtyDayClose":0.2686},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NWBO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-09","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723176000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-05-10","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715313600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-03-05","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1709614800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-09","symbol":"NWBO","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699506000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NWBO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NWBO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NWBO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2562265197","title":"Northwest Biotherapeutics to Acquire Advent BioServices, Streamlining Operations and Enhancing Scale-Up Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2562265197","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562265197?lang=en_us&edition=fundamental","pubTime":"2025-08-28 00:39","pubTimestamp":1756312766,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics, Inc. has announced an agreement to acquire Advent BioServices Ltd. from Toucan Holdings LLC. Upon completion of the transaction, Advent will become a wholly owned subsidiary, allowing Northwest Biotherapeutics to integrate its manufacturing and product development operations internally. This acquisition is expected to enhance operational scalability and yield cost efficiencies. The agreement includes the transfer of Advent's fixed assets and intellectual property to Northwest Biotherapeutics, along with 19 million NWBio securities previously issued to Advent. Payment for the acquisition will be made in installments over two years, starting 90 days post-agreement, with potential acceleration contingent on regulatory approval of the DCVax-L product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nNDL3VnKkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NWBO","BK4139"],"gpt_icon":0},{"id":"2562388726","title":"Northwest Biotherapeutics Announces Agreement to Acquire Advent Bioservices Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2562388726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562388726?lang=en_us&edition=fundamental","pubTime":"2025-08-28 00:39","pubTimestamp":1756312752,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250827:nTUA7SGPLQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2560184927","title":"Northwest Biotherapeutics Announces Management Changes Following Passing of Senior VP and General Counsel Les Goldman","url":"https://stock-news.laohu8.com/highlight/detail?id=2560184927","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560184927?lang=en_us&edition=fundamental","pubTime":"2025-08-19 00:37","pubTimestamp":1755535077,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics Inc. has announced changes in its management team following the passing of its Senior Vice President and General Counsel, Mr. Les Goldman. His responsibilities are being taken over by other members of the company's management team.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on August 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL4Cf6wr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NWBO","BK4139"],"gpt_icon":0},{"id":"2560849741","title":"Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman","url":"https://stock-news.laohu8.com/highlight/detail?id=2560849741","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560849741?lang=en_us&edition=fundamental","pubTime":"2025-08-19 00:37","pubTimestamp":1755535065,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nTUAC3HLM3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NWBO"],"gpt_icon":0},{"id":"2542539121","title":"Northwest Biotherapeutics to Present on Next Generation Dendritic Cell Treatments at Frontiers in Cancer Immunotherapy Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2542539121","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542539121?lang=en_us&edition=fundamental","pubTime":"2025-06-12 00:49","pubTimestamp":1749660577,"startTime":"0","endTime":"0","summary":"Northwest Biotherapeutics to Present on Next Generation Dendritic Cell Treatments at Frontiers in Cancer Immunotherapy Conference. Northwest Biotherapeutics Inc., a company specializing in personalized immune therapies for solid tumor cancers, is set to participate in the Frontiers in Cancer Immunotherapy Conference organized by the New York Academy of Sciences. The event will take place on Monday, June 16. Dr. Marnix Bosch, the company's Chief Technical Officer, will present on \"Next Generation Dendritic Cell Treatments to Improve Anti-Tumor Responses,\" focusing on factors that may enhance the effectiveness of dendritic cells against tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the or","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL13ZDCj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NWBO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}